393 results about "Tumor marker" patented technology

The invention relates to the technical field of medical information processing, in particular to a method for constructing a model for predicting the onset risk of hyperglycemia-related ovarian cancer, which comprises the following steps of: performing isolated analysis on the blood glucose level of a patient during each physical examination, and calculating the blood glucose abnormality of the patient during each physical examination in combination with the local trend characteristics of the blood glucose level, so as to determine the onset risk of hyperglycemia-related ovarian cancer; analyzing the difference between the blood glucose value of the patient and the overall trend information, and evaluating the abnormal blood glucose condition in combination with the abnormal blood glucose degree of the patient; the prediction credibility of the blood glucose value of the patient during each physical examination is calculated by utilizing the incidence relation between the blood glucose value and the tumor marker concentration in different periods and combining the evaluation result of the abnormal blood glucose condition of the patient during each physical examination; therefore, the blood sugar value data is subjected to data cleaning so as to further predict the onset risk of the hyperglycemia-related ovarian cancer of the patient. According to the method, the prediction accuracy of the onset risk of the hyperglycemia-related ovarian cancer is effectively improved.

The invention discloses a novel tsRNA high-sensitivity detection kit based on CRISPR (clustered regularly interspaced short palindromic repeats) / Cas13a-Cas14a, and belongs to the field of tumor marker detection. The tsRNA (tRNA-derived small RNA) is a diagnostic marker which is found recently and has great potential. In order to realize the clinical transformation of tsRNA as soon as possible, the tsRNA detection kit is developed on the basis of nuclease P1 combined with CRISPR / Cas13a-Cas14a linkage dual systems, and comprehensive, ultra-sensitive, high-specificity, low-cost and rapid tsRNA detection is realized through multiple signal amplification. Compared with the traditional technology, the sensitivity of the method is improved by 105-107 times, 1% of tsRNA in the mixture can be detected, and the method has more advantages in clinical application. Therefore, a new scheme is provided for application of the tsRNA in clinical diagnosis of diseases, and meanwhile, a reliable technology is provided for mechanism research of the tsRNA in occurrence and development of the diseases.

Embodiments disclosed herein generally relate to identifying necrotic tissue in a multiplex immunofluorescence image of a slice of specimen. Particularly, aspects of the present disclosure are directed to accessing a multiplex immunofluorescence image of a slice of specimen comprising a first channel for a nuclei marker and a second channel for an epithelial tumor marker, wherein the slice of specimen comprises one or more necrotic tissue regions; providing the multiplex immunofluorescence image to a machine-learning model; receiving an output of the machine-learning model corresponding to a prediction that the multiplex immunofluorescence image includes one or more necrotic tissue regions at one or more particular portions of the multiplex immunofluorescence image; generating a mask for subsequent image processing of the multiplex immunofluorescence image based on the output of the machine-learning model; and outputting the mask for the subsequent image processing.

The invention relates to the technical field of medical treatment, in particular to an intelligent general surgery preoperative risk assessment system which comprises a data acquisition module, a data fusion and processing module, a feature extraction module, a risk assessment module, a prediction and optimization module and a visual display module. The data fusion and processing module adopts a multi-modal data fusion algorithm to generate a patient comprehensive information model, the feature extraction module extracts cardiovascular health status, renal function and tumor marker key features, and the risk assessment module constructs a preoperative risk assessment model to generate a preoperative risk score; the prediction and optimization module predicts the risk of postoperative complications, and the visual display module displays an evaluation result and a prediction result in real time through a graphical interface; according to the method, the accuracy and scientificity of preoperative risk assessment and postoperative complication prediction are remarkably improved, and reliable support is provided for postoperative management of patients.

The invention provides a kit and a method for simultaneously detecting CEA, CA125 and CA153 based on a flow cytometry, which are characterized in that proper microspheres and antibody markers are specially arranged for CEA, CA125 and CA153 antibodies, a 1.5-step incubation method and a biotin system are combined, and proper blocking agents and confining liquid are added into a reaction buffer solution, so that the CA153 in a sample is better combined with the microspheres and the antibody markers, and the detection accuracy is improved. According to the present invention, the cross influence of the CA153 on the CEA and the CA125 is reduced, such that the detection accuracy can be significantly improved when the three tumor markers such as the CEA, the CA125 and the CA153 are simultaneously detected based on the flow cytometry, the detection sensitivity of the CEA can achieve 0.3 ng / mL, the detection sensitivity of the CA125 can achieve 0.5 U / mL, and the detection sensitivity of the CA153 can achieve 0.5 U / mL so as to meet the clinical requirements.

The invention relates to the field of marker detection, in particular to a colorectal cancer tumor marker detection device which comprises a supporting box, the supporting box comprises a bottom plate and a plurality of transverse plates and longitudinal plates which are arranged on the bottom plate, the transverse plates and the longitudinal plates are vertically staggered to form a plurality of rows of placing grooves, and enzyme label strips are placed in the placing grooves; a sliding hole is formed in the end of each transverse plate, sliding grooves are formed in the portions, opposite to the containing grooves, of the sliding holes, and the sliding grooves communicate with the interiors of the sliding holes and the containing grooves. According to the invention, the designed supporting box is matched with the elisa strip, the push rod is arranged in the supporting box, and the push rod is matched with the limiting structure, so that the elisa strip is extruded and fixed in the placing groove, the space of the placing groove is vacated, the elisa strip can be conveniently taken out of the placing groove in an inclined state, and the operation of a detector on the detection process is facilitated.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a detection kit and a detection method for a pretumor marker. The kit comprises an elisa plate coated with a captured antibody, an HRP labeled antibody, an antigen standard substance, a washing solution, a developing solution and a stop solution, the capture antibody and the HRP labeled antibody are both prepared from a monoclonal antibody of the anti-SLC31A1 protein. According to the detection method of the kit for detecting the pretumor marker, the SLC31A1 protein content in human serum is detected through the kit, the specificity is high, a large batch of samples can be rapidly detected in a high-throughput mode, the cancer risk of a to-be-detected crowd can be effectively judged, and therefore relevant patients can find and treat the pretumor marker in advance, treatment prognosis is improved, and the death rate is reduced.

The invention relates to the technical field of bioinformatics, in particular to a tumor marker gene sequence screening method and system, and the method comprises the steps: obtaining a to-be-analyzed gene sequence, an original gene sequence of each tumor marker, and a gene data block of each original gene sequence under each length; obtaining a division evaluation value of each original gene sequence under each length according to the data similarity and difference between the gene data blocks of the original gene sequence and other original gene sequences of the same tumor marker under the same length; obtaining the optimal length according to the difference between the division evaluation values of all the original gene sequences under each length and the adjacent length; dividing the to-be-analyzed gene sequence, and performing hash matching on the to-be-analyzed gene sequence and a division result corresponding to the tumor marker in the database according to the division result to obtain a gene sequence screening result of the tumor marker of the digestive tract patient. According to the method, the block length can be adaptively obtained, and a more accurate gene screening result can be obtained.

The invention relates to the technical field of spectral analysis and biomedical detection, and discloses an SERS (Surface Enhanced Raman Scattering) spectrum quantitative detection method and system based on interpretable stacked ensemble learning. The method comprises the following steps: acquiring SERS spectral data of serum tumor marker standard substances with different concentration gradients; performing baseline correction and normalization preprocessing on the data, performing sparse feature selection by using an LASSO algorithm, and screening out key spectral features to construct a sample data set; constructing an interpretable stacking integration model, wherein the model adopts a base learner layer and a meta learner layer; training the model by using the training set, optimizing model hyper-parameters by using a cross validation strategy, and establishing a mapping relationship between spectral features and tumor marker concentrations; and collecting SERS spectral data of a to-be-detected serum sample, extracting key spectral features, inputting the key spectral features into the trained interpretable stacked integrated model, and outputting a concentration predicted value of the tumor marker in the to-be-detected serum sample. The method has the advantages of high precision, universality and molecular level interpretability.

The invention relates to an HGT tumor marker screening method and device, computer equipment and a storage medium. The method comprises the following steps: extracting microorganisms of a to-be-screened object as target microorganisms; obtaining a gene sequence of the target microorganism as a target gene sequence; obtaining a first HGT event from the target gene sequence; the first HGT event is subjected to normalization, and a normalized first HGT event is obtained; performing reliability verification on the normalized first HGT event to obtain a second HGT event; and according to the second HGT event and a standard HGT event, obtaining the HGT tumor marker probability of the to-be-screened object. The HGT tumor marker probability of the to-be-screened object can be obtained through the HGT event, and the cost is low.

The invention discloses a micro-fluidic chip for detecting breast cancer tumor markers and a preparation method and application thereof, and belongs to the technical field of microfluidics, the preparation method of the micro-fluidic chip comprises the following steps: preparing up-conversion nanoparticles with a core-shell structure through a solvothermal method and a homogeneous wrapping method; the preparation method comprises the following steps: carrying out surface ligand-free treatment on an up-conversion nanoparticle with a core-shell structure, and modifying the up-conversion nanoparticle with ssDNA complementary to a breast cancer tumor marker to obtain the UCNPs-ssDNA fluorescent nanoprobe; the preparation method comprises the following steps: spin-coating a ZnO inverse opal photonic crystal with a UCNPs-ssDNA fluorescent nanoprobe to obtain a photonic crystal / UCNP composite structure; and dispensing the MoS2 nanosheet solution on the composite structure of the photonic crystal / UCNP to obtain the micro-fluidic chip. Compared with the traditional detection means, the micro-fluidic chip has the advantages of low cost, real-time visual detection, high detection sensitivity and the like.

Disclosed herein are methods, compositions, and devices for use in early detection of cancer. The methods include sequencing a panel of regions in cell-free nucleic acid molecules and detecting one or more tumor markers that are indicative of a cancer.

The invention relates to the technical field of tumor markers, in particular to a pancreatic cancer early screening marker combination based on blood protein and application of the pancreatic cancer early screening marker combination. Through proteomics analysis and bioinformatics screening, 12 kinds of proteins such as NME3, HPGDS, CEACAM5, TNFSF12, SCG3, VTCN1, GFRA1, KRT19, TMPRSS12, NELL2, KAZALD and MMP12 are determined to serve as the potential early screening markers of the pancreatic cancer. Researches show that the combination of the proteins can effectively distinguish pancreatic cancer patients from non-pancreatic cancer patients, and has good sensitivity and specificity. A screening model constructed based on the protein combination can be applied to auxiliary diagnosis, risk assessment and population screening of pancreatic cancer, and has important clinical transformation value.

To provide a novel squaraine dye-peptide complex that enables selective detection of esterase, being one of tumor markers.SOLUTION: A squaraine dye-peptide complex is prepared by incorporating an oligopeptide between two squaraine dyes represented by formula (1), where R1B and R2B each independently represent a C1 to C30 monovalent aliphatic hydrocarbon group, with at least one having a carboxyl group at a terminal, and R3B and R4B each independently represent H or a carboxyl group, with at least one being a carboxyl group.SELECTED DRAWING: Figure 3

The invention discloses a system, equipment or medium for diagnosing or predicting breast cancer based on methylation marker combination, and belongs to the technical field of tumor markers. Wherein the methylation marker combination comprises a methylation gene combination, and the methylation gene combination comprises MLLT6, AR1, MED24, KCTD11, AADAT, PTPRN2, ACTR1A, CELSR1, ZC3H7A, TRIM8, IGLL5, CORO2B, THADA, CNNM1, SLC16A3, DEAF1 and LCP2. The invention further discloses a kit for detecting the methylation marker combination. A machine learning model is constructed by using methylation level data of the methylation marker combination, and the machine learning model can be used for diagnosing whether a subject suffers from the breast cancer or predicting whether the subject has the risk of suffering from the breast cancer, and has huge clinical application value.

Methods for detecting a tumor using a sample in which tumor DNA fragments are present only in a very low concentration, beyond the statistical limit of detection, where methods include: obtaining sequence data for tumor nucleic acid from a tumor from a subject and analyzing the sequence data to identify a plurality of tumor-specific variants that are in the tumor nucleic acid and that are not in non-tumor nucleic acid of the subject; selecting a marker variant that appears duplicated in tumor nucleic acid (compared to non-tumor nucleic acid) a greater number of times than other ones of the tumor variants; performing an assay to detect the marker variant in a sample from the subject; and reporting the presence of the tumor in the subject when the assay is positive for the marker variant in the sample.

The invention belongs to the technical field of biomedical detection, and discloses a Raman spectrum analysis device for quantitative detection of hematologic tumor markers, which comprises a blood collection centrifugal unit with a self-adaptive load regulation mechanism for monitoring blood density and components in real time, centrifugal force and time parameters are automatically adjusted according to the blood density and components; the optical fiber Raman spectrometer is provided with an automatic wavelength calibration system, and an ultrafast laser pulse transmitter and a high-sensitivity photon counting detector are integrated on the optical fiber Raman spectrometer. Raman scattering signals are enhanced by adopting a quantum entanglement light source and a nonlinear optical crystal; according to the invention, the detection capability on low-concentration tumor markers can be obviously improved. Due to the improvement, the device can accurately detect the existence of the tumor marker at the early stage of cancer, and powerful support is provided for early treatment of a patient.

The invention discloses an immune quantitative detection device for tumor markers, relates to the technical field of medical detection, and aims to solve the problems of complicated operation, long detection period and poor portability in immune quantitative detection of tumor markers in the prior art. Comprising a shell, a disposable detection card, a multi-channel micro-fluidic chip, a high-sensitivity sensing system, a micro magnetic control incubation module, an AI auxiliary image recognition system and a wireless transmission module, the disposable detection card is used for accommodating the multi-channel micro-fluidic chip and a reaction reagent, and the multi-channel micro-fluidic chip is respectively aligned with the high-sensitivity sensing system and the micro magnetic control incubation module; the high-sensitivity sensing system is composed of a surface plasma resonance sensor and a quantum dot fluorescence labeling module, and the surface of a sensing chip of the surface plasma resonance sensor is modified with a tumor marker specific capture antibody. The method has the advantages of convenient detection and high efficiency and precision.

Disclosed herein are methods, compositions, and devices for use in early detection of cancer. The methods include sequencing a panel of regions in cell-free nucleic acid molecules and detecting one or more tumor markers that are indicative of a cancer.

The invention provides a tumor marker multi-item quality control product, and belongs to the crossing field of synthetic biology and in vitro diagnostic reagents, the tumor marker multi-item quality control product provided by the invention can at most comprise 25 tumor markers including a recombinant gastrin releasing peptide precursor and recombinant gastrin 17, and has the advantages of wide and complete coverage items, stable performance, low cost, high efficiency and the like. The preparation process is stable and simple, the difference between bottles is small, the production cost is low, and the method is particularly suitable for daily quality control monitoring of a detection mechanism.

The invention provides a serum tumor marker detection array optimization method and system.The method is applied to a control module of an array device.The method comprises the steps that when a multi-needle detection platform conducts serum tumor marker detection on a preset sample, preliminary expression information sent by the multi-needle detection platform is obtained; acquiring patient medical history information, iconography information and pathology information corresponding to the preset sample; inputting the preliminary expression information, the patient medical history information, the iconography information and the pathology information into a pre-constructed Bayesian analysis model, and outputting a prediction weight, a prediction disease progress direction and a correlation marker corresponding to each tumor marker to generate target information; wherein the target spot information comprises a plurality of target markers; and controlling the multi-needle detection platform to perform serum tumor marker detection on the preset sample again according to the target spot information to complete array optimization of serum tumor marker detection. Therefore, an efficient and innovative solution is provided for early diagnosis and monitoring.

A method for evaluating the risk of having a tumor or a specific tumor, which relates to the technical field of tumor markers. The method for evaluating the risk of having a tumor for a non-diagnostic purpose comprises the following steps: detecting a marker in a peripheral blood sample by means of taking circulating tumor-immune chimeric cells as the marker, wherein the higher the number of the marker is, the higher the tumor malignancy degree is. By means of separating, identifying and counting the target marker, i.e., circulating tumor-immune chimeric cells in a detection sample, a doctor can be assisted in evaluating and screening a suspected cancer patient, and the occurrence of clinical missed diagnosis or misdiagnosis of cancer is reduced.

The invention discloses an electrochemically actuated biosensor for actively capturing tumor markers and a detection method. The electrochemical actuation biosensor comprises an electrochemical driver with a three-layer structure, wherein the electrochemical driver is composed of two identical MXene-Au electrode layers and a middle inert film; according to the MUC1 actuated biosensing detection method of the electrochemical driver based on the MXene-Au electrode layer, under the action of electrochemical CV circulation, the electrochemical driver with AuNPs coupled with the MUC1 aptamer on the surface of the electrode layer can actively capture a tumor marker MUC1 far away from an electrode area. According to the application, the actuation performance and the biosensing performance can be simultaneously improved through the AuNPs subjected to in-situ reduction on MXene, an actuation and biosensing dual-promotion effect is achieved, the binding efficiency of the bendable electrode and biomolecules is improved, further, more target molecules MUC1 are recognized, and ultra-sensitive biological detection is realized.

The invention discloses a big data-based digestive system department prediction analysis system. The system comprises a data acquisition module, a knowledge graph fusion module, a disease course evolution prediction module and an intelligent diagnosis and treatment decision module. The invention relates to the technical field of medical health information, in particular to a big-data-based predictive analysis system for the department of gastroenterology. According to the scheme, a physiological signal is reconstructed by using a multi-scale mask auto-encoder, and the signal and a text are aligned; mapping knowledge graph regularization is introduced, the joint code is mapped to a digestive system knowledge graph space, and medical semantic representation is obtained; constructing a time sequence attenuation dynamic graph through the dynamic memory graph, and adding graph convolution gating; an embedded differential equation module simulates inflammation and tumor marker evolution to realize accurate prediction; patient state vectors are constructed based on multi-modal coding, medicines are rapidly selected by using a scoring function, a treatment process is modeled as a Markov decision, and a strategy network, a value network and PPO optimization are combined to realize balance of curative effect and income.

This invention relates to aggregation-induced emission probes with specific responses to tumor markers and their applications, belonging to the field of biochemistry. This invention utilizes molecular structure modulation to prepare a series of molecules possessing large Stokes shifts, resistance to photobleaching, near-infrared II (NIR-II) emission, and aggregation-induced emission properties. Different self-eliminating groups are attached to the dimethylamino group of the molecule via quaternization or to the pyridine group via pyridinium salting. By controlling the structure of these self-eliminating groups, activatable luminescent probes responding to different tumor markers can be constructed. These probes integrate deep NIR-II imaging, aggregation-point luminescence, large Stokes shifts, and marker-specific responses, providing a new approach for precise imaging diagnosis of tumors.

The invention provides an activatable semiconductor polymer as well as a preparation method and application thereof. The activatable semiconductor polymer disclosed by the invention can be efficiently accumulated at a tumor site, due to the existence of a side chain electron withdrawing group, the fluorescence of the polymer is in a quenched state, the fluorescence of the polymer is recovered after tumor markers such as biological mercaptans, active oxygen and cathepsin B are respectively responded, and accurate imaging and sonodynamic therapy can be carried out at the tumor site. Meanwhile, the activatable semiconductor polymer can mark immune cells (such as dendritic cells and macrophages) and track the process of transferring the immune cells from tumors to tumor drainage lymph nodes.

The invention relates to the technical field of biology, in particular to an eccDNA marker and application thereof in prognosis prediction of colorectal cancer. According to the present invention, the chromosome outer circular DNA is adopted as the colorectal cancer prognosis prediction marker, and the colorectal cancer prognosis prediction marker is significantly superior to the common tumor marker when the colorectal cancer prognosis prediction marker is used; a colorectal cancer prognosis prediction model constructed by adopting the eccDNA marker provided by the invention is high in diagnosis accuracy, high in sensitivity and strong in specificity, and has excellent application potential in clinical risk stratification.

The invention discloses a brain tumor real-time identification system and method based on cortical electroencephalogram signals, and relates to the technical field of medical artificial intelligence, and the method comprises the following steps: obtaining multi-channel ECoG signals in real time; the multi-channel ECoG signals are updated in real time, the multi-channel ECoG signals updated in real time are preprocessed, and the preprocessed multi-channel ECoG signals are obtained; performing channel feature extraction on the ECoG signal of each channel to obtain various ECoG signal features under each channel as channel features; calculating segmentation thresholds of different channel characteristics under each channel based on an automatic threshold segmentation algorithm; carrying out confidence evaluation on the segmentation threshold values of different channel characteristics under each channel; and marking the channel of which the confidence coefficient is smaller than a set tumor marking threshold value as a tumor area. Accurate positioning of a tumor area can be achieved, functional state changes of the cerebral cortex can be reflected in real time, and doctors can conveniently master real-time changes of cortex functions in time.

Provided is a methylated tumor marker STAMP-EP2 and uses thereof in preparing a tumor diagnostic reagen. The tumor marker STAMP-EP2 herein is hypermethylated in all tumor types, is hypomethylated in corresponding normal tissue, and has high sensitivity and specificity; primers for detecting STAMP-EP2 may be used to prepare a tumor diagnostic kit.

Methods for creating a selector of mutated genomic regions and for using the selector set to analyze genetic alterations in a cell-free nucleic acid sample are provided. The methods can be used to measure tumor-derived nucleic acids in a blood sample from a subject and thus to monitor the progression of disease in the subject. The methods can also be used for cancer screening, cancer diagnosis, cancer prognosis, and cancer therapy designation.